Hormone Sensitive Prostate Cancer Clinical Trials
0 recruiting
Showing 1–5 of 5 trials
Recruiting
Phase 3
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Prostate CancerCancer of the ProstateHormone Sensitive Prostate Cancer+1 more
Pfizer1,000 enrolled188 locationsNCT07028853
Recruiting
Phase 2
PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer
Prostate CancerProstate AdenocarcinomaHormone Sensitive Prostate Cancer
University of Miami34 enrolled1 locationNCT06392295
Recruiting
Phase 3
Metastasis-directed Therapy for Oligorecurrent Prostate Cancer
Prostate CancerMetastatic CancerProstate Cancer Metastatic+4 more
Universitaire Ziekenhuizen KU Leuven873 enrolled1 locationNCT05352178
Recruiting
Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Agent (Alone or Combined) or Radiotherapy on Primary Tumor in Addition to Androgen Deprivation Therapy in HOrmone-Sensitive Metastatic Prostate Cancer Patients
Prostate CancerMetastatic TumorHormone Sensitive Prostate Cancer
Santa Chiara Hospital3,000 enrolled3 locationsNCT06473259
Recruiting
Phase 3
Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC
Chemotherapy EffectMetastatic Prostate CancerHormone Sensitive Prostate Cancer
The First Affiliated Hospital with Nanjing Medical University200 enrolled1 locationNCT05983783